DEFM14A: Horizon Space II to Merge with SL Bio in $5.568B Deal

Horizon Space Acquisition II Corp. (HSPT) announces a definitive business combination agreement with SL BIO Ltd. (SL Bio), valuing SL Bio at $5.568 billion, with the combined entity, PubCo, to list on Nasdaq under 'SLBT'.

Summary

• Horizon Space Acquisition II Corp. (HSPT), a SPAC, is merging with SL BIO Ltd. (SL Bio), a biomedical company, through a two-step merger to form SL Science Holding Limited (PubCo).
• The Business Combination Agreement was signed on May 9, 2025, valuing SL Bio at $5.568 billion.
• PubCo Ordinary Shares are expected to be listed and traded on Nasdaq under the symbol 'SLBT' following the consummation of the Business Combination.
• HSPT shareholders and SL Bio shareholders will receive PubCo Ordinary Shares, leading to immediate dilution for HSPT Public Shareholders.
• The combined entity's liquidity is estimated at $77.6 million assuming no redemptions and $9.5 million assuming maximum redemptions, after securing a $5.0 million Transaction Financing.
• SL Bio specializes in innovative cellular and gene therapies, including Armed-T and Gamma Delta T cells for cancer treatment, and exosome applications in skincare and cancer recovery.
• All three product candidates (CD-19 Armed-T Therapy, GDT Cells therapies for pancreatic and brain cancer) are currently in pre-clinical trials.
• The IND application process for the blood cancer program is expected in Q1 2026.
• SL Bio has licensed CD-19 Armed-T technology from CytoArm and GDT cell culture technology from JY BioMed, with potential milestone payments of up to $4.1 million and $37 million, respectively, plus royalties on sales.
• SL Bio reported a net loss of $1,602,089 for the six months ended June 30, 2025, and a net loss of $1,191,333 for the year ended December 31, 2024.
• HSPT's board unanimously recommends voting FOR all proposals related to the Business Combination.
• PubCo will operate as a foreign private issuer and a controlled company under Nasdaq rules, which may allow exemptions from certain corporate governance requirements.
• SL Bio has identified material weaknesses in its internal control over financial reporting related to staffing and formal procedures, with remediation measures underway.

Sentiment

Score: 3

Explanation: The filing outlines a significant merger with a biomedical company in a high-growth sector. However, SL Bio is in early development stages with no approved products, has increasing losses, and identified material weaknesses in internal controls. The transaction involves substantial dilution for public shareholders, and the required financing is not yet secured. These factors, combined with regulatory uncertainties and reliance on key licenses, present considerable risks.

Positives

• SL Bio's focus on innovative cellular and gene therapies (Armed-T, Gamma Delta T cells) for cancer treatment and regenerative medicine positions it in a high-growth sector.
• Proprietary technologies like Armed-T and GDT cells have the potential to revolutionize the biopharmaceutical industry.
• Strategic partnerships and licensing agreements with CytoArm and JY BioMed provide access to key intellectual property and expertise.
• The target markets for SL Bio's cancer therapeutics are large and underserved, with the global blood cancer market projected to reach $73.66 billion by 2034, pancreatic cancer to $10.69 billion by 2032, and brain cancer to $4.42 billion by 2032.
• The management team of the combined entity brings deep expertise in biotech and finance.
• The expected Nasdaq listing for PubCo is anticipated to enhance visibility and provide access to public market capital for funding growth plans.
• A fairness opinion from King Kee Appraisal and Advisory Limited (KKG) concluded that the transaction is fair to HSPT shareholders from a financial perspective.
• The combined liquidity of approximately $77.6 million (assuming no redemptions and $5.0 million Transaction Financing) is expected to fund preclinical trials and well into Phase I trials for key product candidates in 2026.

Negatives

• SL Bio is an early-stage company with limited operating history and no products currently approved for commercial sale, introducing significant commercialization risk.
• The company is highly dependent on license agreements with CytoArm and JY BioMed; termination of these agreements could severely impact product commercialization.
• SL Bio has incurred significant net losses, reporting $(1,602,089) for the six months ended June 30, 2025, and $(1,191,333) for the year ended December 31, 2024.
• Gross profit decreased by 63% from $1,065,727 in H1 2024 to $389,066 in H1 2025, primarily due to a shift to lower-margin corporate sales.
• Total operating expenses increased by 28% to $1,998,808 in H1 2025, largely driven by a 112% increase in general and administrative expenses due to senior management expansion.
• The required Transaction Financing of at least $5.0 million is not yet committed, posing a risk to the satisfaction of closing conditions and future liquidity.
• HSPT Public Shareholders will experience immediate and significant dilution, with ownership potentially decreasing to 0.17% in a maximum redemption scenario.
• Conflicts of interest exist for HSPT's directors and officers due to their financial interests in the Business Combination, as their founder shares would become worthless if the merger is not completed.
• SL Bio relies on a single-source supplier (YC Biotech Co., Ltd.) for the development, manufacturing, and packaging of its exosome products, creating supply chain risk.
• Material weaknesses in SL Bio's internal control over financial reporting have been identified, indicating potential operational and financial reporting deficiencies.
• Uncertainty surrounds the FDA's regulatory classification and approval pathway for SL Bio's novel cell therapy and exosome products in the U.S.
• The listing of PubCo's securities on Nasdaq will not benefit from the traditional underwritten IPO process, potentially leading to diminished investor demand and increased price volatility.
• PubCo's status as a foreign private issuer and controlled company may result in corporate governance practices that offer less protection to shareholders compared to U.S. domestic issuers.
• The Business Combination may be a taxable event for U.S. Holders of HSPT and/or SL Bio Ordinary Shares, and PubCo may become a Passive Foreign Investment Company (PFIC), leading to adverse tax consequences.

Risks

• SL Bio is highly dependent on its license agreements with CytoArm Co., Ltd. and Ji Yan BioMedical Co., Ltd., the termination of which would prevent commercialization of its products and imposes significant obligations.
• The equity value of SL Bio is highly dependent on these license agreements, and certain officers or directors may have actual or potential conflicts of interest due to their equity interests in CytoArm and JY BioMed.
• SL Bio may not be able to manage its potential growth effectively, which could place significant strain on its management, operational, and financial resources.
• SL Bio may require additional funding to implement its business plan and may not be able to secure such financing on favorable terms or at all, potentially leading to substantial dilution of existing shareholders.
• SL Bio's business will continue to require substantial expenditures before profits, if any, are realized, and there is no assurance an adequate revenue base will be established.
• Difficulties or delays in the development, introduction, or marketing of enhanced or new medical products, including the risk that clinical testing may not yield successful results.
• Even if medical products receive marketing clearance or approval, they may fail to achieve sufficient market acceptance by physicians, patients, and third-party payors.
• SL Bio may be subject to intellectual property infringement claims, which could incur litigation costs and divert management attention, and its protective measures may be inadequate.
• The PCAOB's historical inability to inspect SL Bio's auditor in Hong Kong could lead to future trading prohibitions under the HFCAA, adversely affecting investment value.
• Investment may be adversely affected by political considerations relating to Taiwan, where SL Bio's major subsidiary is located.
• The imposition of foreign exchange restrictions in Taiwan may adversely affect the company's ability to repatriate dividends.
• Natural disasters and other events outside of the company's control in Taiwan may seriously disrupt business operations.
• Currency fluctuations and restrictions on currency exchange in Taiwan may adversely affect business, including limiting the ability to convert NTD into foreign currencies.
• Recent reductions in force across the U.S. federal government (e.g., FDA, HHS) may impact the ability to secure necessary meetings, guidance, and product approvals.
• Uncertainty regarding how the FDA will regulate SL Bio's products (drugs, medical devices, or cosmetics) may cause delays and increased costs for market entry in the U.S.
• Exosome products will likely be subject to heightened FDA scrutiny, which could impede or prevent marketing in the U.S. and increase the risk of consumer action.
• Cell therapy products represent a novel approach, increasing the uncertainty of the pathway to market and regulatory approval.
• There is no assurance that the FDA will ever permit the company to market any new product or service, or that any regulatory clearance or approval, once obtained, may not be withdrawn.
• Delays in the commencement or conduct of required clinical trials could result in increased costs and delay the ability to pursue regulatory clearance or approval.
• Delays or difficulties in the enrollment of patients in clinical trials could delay or prevent necessary regulatory approval or clearance.
• Product candidates that advance into clinical trials may not receive regulatory clearance or approval, even after promising early results.
• Approved products will remain subject to substantial regulatory scrutiny, and later identification of undesirable side effects or non-compliance could lead to significant negative consequences.
• Healthcare reform measures in the U.S. could hinder or prevent product commercial success, including reductions in Medicare reimbursement rates.
• Product liability lawsuits against the company could cause substantial liabilities and limit commercialization of products.
• Compliance with HIPAA security, privacy, and breach notification regulations may increase costs.
• Employees, independent contractors, consultants, commercial partners, and vendors may engage in misconduct or other improper activities, leading to regulatory sanctions or lawsuits.
• HSPT will have limited rights after the closing to make claims for damages against SL Bio or its shareholders for breach of representations, warranties, or covenants.
• PubCo may be required to take write-downs or write-offs, restructuring, and impairment or other charges that could have a significant negative effect on its financial condition and share price.
• HSPT Initial Shareholders own shares that will be worthless if the Business Combination is not approved, creating a potential conflict of interest in their decision to recommend the merger.
• HSPT Public Shareholders will experience immediate dilution as a consequence of the issuance of PubCo Ordinary Shares and Transaction Financing.
• The conversion of any working capital loans or extension loans into working capital units or extension units may result in significant dilution to HSPT Public Shares.
• The exercise of HSPT's directors' and officers' discretion in agreeing to changes or waivers in the terms of the Business Combination Agreement may result in a conflict of interest.
• If HSPT is unable to complete the Business Combination within the prescribed timeline, HSPT Public Shareholders may receive only approximately $10.53 per public share, or less, and HSPT Rights will expire worthless.
• If Transaction Financing or other equity financing is not available prior to or upon the closing of the Business Combination, the merger may not be consummated.
• HSPT Public Shareholders may be held liable for claims by third parties against HSPT to the extent of distributions received by them.
• Activities taken by existing HSPT shareholders to increase the likelihood of approval of the Business Combination Proposal could have a depressive effect on HSPT Ordinary Shares.
• HSPT is dependent upon its current executive officers and directors, and their loss could adversely affect its ability to operate.
• The HSPT Initial Shareholders have agreed to vote in favor of the Business Combination, regardless of how HSPT Public Shareholders vote, potentially reducing the influence of public shareholders.
• The fairness opinion delivered by KKG will not reflect changes in circumstances between the date of the Business Combination Agreement and the completion of the Business Combination, and was based on financial projections that may prove incorrect.
• If the Business Combination's benefits do not meet investor expectations, the market price of PubCo Ordinary Shares may decline.
• Broad market and industry factors may materially harm the market price of PubCo Ordinary Shares irrespective of operating performance.
• HSPT's directors may decide not to enforce the indemnification obligations of the Sponsor, resulting in a reduction of funds available for public shareholders.
• Members of HSPT's management team may be involved in governmental investigations, regulatory proceedings, and civil litigation, diverting attention and harming reputation.
• HSPT may become involved in litigation that may materially adversely affect it.
• The Business Combination is subject to conditions, including certain conditions that may not be satisfied on a timely basis, if at all.
• Either HSPT or SL Bio may waive one or more of the conditions to the Business Combination, potentially against the interests of some shareholders.
• Termination of the Business Combination Agreement could negatively impact both HSPT and SL Bio.
• The listing of PubCo's securities on Nasdaq will not benefit from the process undertaken in connection with an underwritten initial public offering, potentially leading to diminished investor demand and higher volatility.
• There is no guarantee that a shareholder's decision to hold PubCo Ordinary Shares will result in a better economic position than if they redeemed their HSPT Public Shares.
• If HSPT shareholders fail to comply with redemption requirements, they will not be entitled to redeem their shares.
• Shareholders holding more than 15% of HSPT Public Shares will lose the ability to redeem excess shares.
• HSPT Public Shareholders will not have any rights or interests in funds from the Trust Account, except under certain limited circumstances, forcing them to sell shares potentially at a loss.
• If HSPT is deemed an investment company under the Investment Company Act, its activities may be restricted, potentially forcing liquidation.
• The Business Combination may be subject to U.S. foreign investment regulations and review by CFIUS, potentially delaying or prohibiting it.
• Changes in laws or regulations related to business combination transactions involving SPACs may materially adversely affect HSPT's ability to complete the merger.
• A new 1% U.S. federal excise tax could be imposed on HSPT in connection with redemptions.
• The price of PubCo's securities may be volatile, and the value of its securities may decline.
• The process of taking a company public by means of a business combination with a SPAC may create risks for PubCo's unaffiliated investors compared to a conventional IPO.
• As a controlled company under Nasdaq rules, PubCo may choose to exempt itself from certain corporate governance requirements, which could adversely affect public shareholders.
• PubCo will become a foreign private issuer, resulting in less frequent and lenient Exchange Act reporting obligations and exemptions from U.S. proxy rules and insider trading provisions.
• If PubCo ceases to qualify as a foreign private issuer, it would incur significant additional legal, accounting, and other expenses.
• If PubCo cannot satisfy Nasdaq listing requirements, its securities may not be listed or may be delisted, negatively affecting price and liquidity.
• As a Cayman Islands exempted company, PubCo is permitted to adopt home country corporate governance practices that differ significantly from Nasdaq standards, potentially affording less protection to shareholders.
• Shareholders may face difficulties in protecting their interests and enforcing rights through U.S. courts due to PubCo's incorporation in the Cayman Islands and operations in Taiwan.
• The Amended PubCo Charter contains certain anti-takeover provisions that could delay or discourage takeover attempts.
• A market for PubCo's securities may not develop or be sustained, adversely affecting liquidity and price.
• If PubCo fails to implement and maintain effective internal controls to remediate its material weakness over financial reporting, it may be unable to accurately report results, meet obligations, or prevent fraud.
• The issuance of additional share capital in connection with financings, acquisitions, investments, or equity incentive plans will dilute all other shareholders.
• PubCo does not intend to pay dividends before it becomes profitable, meaning returns will depend on share price appreciation.
• A significant portion of issued and outstanding PubCo Ordinary Shares may be sold into the market in the near future, potentially causing the market price to drop significantly.
• As an emerging growth company, PubCo's reduced reporting and disclosure requirements may make its securities less attractive to investors.
• PubCo will incur increased costs as a public company, and management will devote substantial time to compliance.
• PubCo may be or become a passive foreign investment company (PFIC), which could result in adverse U.S. federal income tax consequences to U.S. Holders.

Future Outlook

PubCo's management anticipates that with no redemptions and the successful obtainment of $5.0 million in Transaction Financing, the combined entity would have approximately $74.1 million in net proceeds. This capital is expected to be sufficient to fund the advancement of its CD-19 Armed-T and Gamma Delta T product candidates through preclinical trials and well into Phase I trials in 2026. However, if redemptions reach a 50% level, additional funds would be required to fully fund Phase I trials, and at maximum redemptions, additional funds would be needed just to begin Phase I trials. SL Bio plans to gradually phase out its legacy exosome cosmetic and plant supplement businesses as its cell therapies for cancer treatment mature.

Management Comments

• "SL Bio hopes to utilize immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products."
• "With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery, SL Bio aims to create cellular therapies which we believe have the potential to revolutionize the biopharmaceutical industry."
• "PubCo's management believes that PubCo would have resources sufficient to fund the advancement of its CD-19 Armed-T and Gamma Delta T product candidates through preclinical trials well into Phase I trials in 2026." (assuming no redemptions and $5M financing)
• "SL Bio's clinical development strategy is intended not only to obtain FDA regulatory approval but also to commercialize our CD-19 Armed-T products, if supported by favorable clinical trial results."
• "We anticipate formalizing these partnerships or licensing arrangements if the data from Phase II clinical trials provide evidence of safety and efficacy sufficient to warrant further development."
• "By focusing on these two critical indications [pancreatic and brain cancer], we hope to address significant unmet medical needs and provide effective, accessible treatments to improve patient outcomes."
• "We expect that as our cell therapies for cancer treatment mature, we will gradually phase out our legacy exosome cosmetic and plant supplement businesses."

Industry Context

The blood cancer therapeutics market is experiencing robust growth, projected to reach approximately $73.66 billion by 2034, driven by increasing disease prevalence, early diagnosis awareness, and advancements in precision medicine and immunotherapy. Similarly, the pancreatic cancer treatment market is expected to grow from $3.3 billion in 2024 to $10.69 billion by 2032, and the brain tumor treatment market from $2.07 billion in 2024 to $4.42 billion by 2032, both propelled by urgent unmet medical needs and technological innovations like GDT cell therapies. The exosome cosmetics market is also expanding, projected to reach $796 million by 2031 globally, and $73.58 million in the U.S. by 2023 with a projected CAGR of 34.2% from 2024 to 2030, fueled by consumer demand for science-backed, regenerative skincare. The plant extract cosmetics market, a well-established segment, is also growing, driven by demand for natural and sustainable solutions. SL Bio aims to position itself as a potential leader in the next-generation allogeneic cell therapy industry, with a particular focus on GDT cell-based oncology treatments and engineered immune effector cell platforms.

Comparison to Industry Standards

• The global blood cancer therapeutics market is projected to grow at a CAGR of 6.35% from 2025 to 2034, while the estimated growth rate of new cell drugs is 22.66% (Grand View Research). SL Bio's projected market share for its CD-19 Armed-T drug is 15% of an $11.82 billion market by 2031.
• The global pancreatic cancer treatment market is projected to grow from $3.3 billion in 2024 to $10.69 billion by 2032. SL Bio projects a 20% market share for its GDT new pancreatic cancer drug, based on expected advantages in safety and effectiveness.
• The global brain tumor treatment market is projected to grow from $2.07 billion in 2024 to $4.42 billion by 2032. SL Bio projects a 15% market share for its GDT new brain cancer drug.
• The global exosome skincare market is projected to grow at a CAGR of 9.6% from 2024 to 2031, with the U.S. market alone projected at a CAGR of 34.2% from 2024 to 2030.
• The broader plant extracts industry, which includes plant extract cosmetics, is projected to grow at a CAGR of 11.04% from 2024 to 2034.
• SL Bio's GDT cells are positioned as an advanced allogeneic cell therapy, offering advantages such as low residual T cell contamination, high expression of key markers (CD3, V2, NKG2D), broader anti-tumor activity, and lower risk of graft-versus-host disease (GvHD) compared to conventional T cells.
• SL Bio's Armed-T therapy aims to utilize bispecific antibodies without genetic modification, differentiating it from conventional CAR-T therapies (e.g., Novartis Kymriah, Gilead Yescarta) which involve genetic modification and are associated with high manufacturing complexity and severe side effects like cytokine release syndrome and neurotoxicity.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the filing, there are no pending or, to the knowledge of the Company or Acquiror, threatened lawsuits, claims, proceedings, or investigations against the Company, its Subsidiaries, or Acquiror, or their respective properties or assets, involving an amount exceeding $200,000 (for SL Bio) or material to the business (for HSPT).
• There are no outstanding Governmental Orders specifically directed at and imposed upon the Company, its Subsidiaries, or Acquiror, or any of their respective properties or assets.
• No current or pending internal investigations or, to the knowledge of the Company, third-party investigations (including by any Governmental Authority) or audits address any material allegations concerning possible material violations of Anti-Bribery Laws related to the Company or its Subsidiaries.
• There have been no pending or, to the knowledge of the Company, threatened claims, complaints, charges, investigations, voluntary disclosures, or Legal Proceedings against the Company or its Subsidiaries related to violations of Anti-Money Laundering Laws, Sanctions, or International Trade Laws for the past four years.

Related Party Transactions

• HSPT's Sponsor acquired 1,725,000 Founder Shares for approximately $0.0145 per share and transferred 60,000 Founder Shares to independent directors and 10,000 to the CFO at the original purchase price.
• HSPT's Sponsor loaned HSPT $300,000 for working capital on July 5, 2025, evidenced by an unsecured promissory note, which is non-interest bearing and convertible into private units at $10.00 per unit at the lender's discretion.
• An amount of $254,484 was due to the Sponsor from HSPT as of September 30, 2025, representing advancements for formation expenses and a portion of IPO expenses.
• Hsiao-Lan Wu, a third party to the Sponsor and HSPT, deposited $690,000 into the Trust Account on November 17, 2025, to extend the business combination period, evidenced by an unsecured promissory note convertible into HSPT Private Units at $10.00 per unit.
• HSPT and the Sponsor agreed to waive full payment of the Administrative Service Fee of $10,000 per month for up to 12 months, totaling $120,000.
• Mr. William Wang, SL Bio's CEO and Chairman, owns an indirect interest of approximately 12.6% in CytoArm, from which SL Bio licenses CD-19 Armed-T technology.
• Dr. Ethan Shen, SL Bio's CTO, served as CEO of JY BioMed until August 1, 2025, and became Chairman of JY BioMed on December 1, 2025, holding a 76.0% equity stake in JY BioMed, from which SL Bio licenses GDT cell culture technology.
• SL Bio paid $949,771 to SL Link (a company controlled by Mr. Wang) for the transfer of the CD-19 Armed-T Licensed Patent, equivalent to SL Link's prior R&D costs.
• SL Bio paid $1 million to JY BioMed for initial research and development costs and material costs of GDT cell therapy products.
• An amount of $491,429 was due to JY BioMed from SL Bio as of June 30, 2025, for other payables, interest-free and payable on demand.
• SL Bio previously had an operating lease arrangement and a corporate and administrative service agreement with SL Link, both terminated in December 2024.
• SL Link and SL Bio expect to enter into a non-compete agreement immediately prior to the consummation of the Business Combination.

Stakeholder Impact

• **Shareholders (HSPT Public)**: Will experience immediate and significant dilution in ownership and voting interest in PubCo. Their ability to redeem shares is subject to specific requirements and limitations (e.g., 15% cap). There is no guarantee that holding PubCo shares will yield a better economic position than redeeming HSPT Public Shares.
• **Shareholders (HSPT Initial/Sponsor)**: Have a strong incentive to complete the Business Combination as their founder shares and private units would become worthless if the merger fails. Their voting power in PubCo will be less than 1% immediately after the Second Closing, significantly reducing their influence.
• **Shareholders (SL Bio)**: Will become shareholders of a publicly traded company (PubCo) on Nasdaq, potentially enhancing liquidity and access to capital for their investment.
• **Employees (SL Bio/PubCo)**: The management team of PubCo will largely consist of current SL Bio management. There are plans to expand the workforce, including hiring a Chief Medical Officer, to strengthen biomedical capabilities.
• **Customers**: Potential for new and advanced cellular and gene therapies for cancer treatment, as well as continued availability of exosome and plant extract cosmetic products (though the latter are planned to be phased out).
• **Suppliers**: SL Bio's reliance on a single-source supplier (YC Biotech) for exosome products poses a risk to supply chain stability.
• **Creditors**: If HSPT liquidates without completing a business combination, third-party claims could reduce the funds available in the Trust Account for public shareholders, potentially making HSPT Public Shareholders liable to the extent of distributions received.

Next Steps

• HSPT shareholders to vote on the Business Combination Proposals, Amended M&A Proposal, Sole Director Appointment Proposal, and Adjournment Proposal at the Extraordinary General Meeting on February 3, 2026.
• PubCo and SL Bio to use reasonable best efforts to obtain at least $5,000,000 in Transaction Financing prior to or upon the Second Merger Closing.
• The IND application process for SL Bio's blood cancer program is expected in Q1 2026, followed by Phase I, II, and III clinical trials.
• IND-enabling studies for SL Bio's Gamma Delta T Cell (GDT) platform are to be completed in Q1 2026, with IND submission in 2026.
• PubCo will apply for Nasdaq listing of its Ordinary Shares under the symbol 'SLBT'.
• PubCo will adopt a new code of business conduct and ethics and an insider trading policy.
• SL Bio intends to gradually phase out its exosome cosmetic and plant supplement businesses as its cell therapies for cancer treatment mature.
• PubCo will establish an audit committee, compensation committee, and nominating and corporate governance committee with independent directors.
• PubCo will enter into customary indemnification agreements with its post-Second Closing directors and officers.
• SL Link will enter into a non-compete agreement with SL Bio regarding CD-19 Armed-T products and GDT cell therapy product candidates.

Key Dates

Recommendation

The proposed business combination offers exposure to the high-growth biomedical sector, particularly in innovative cell and gene therapies for cancer. However, SL Bio is an early-stage company with no approved products, significant R&D expenditures, and a history of net losses. The transaction involves substantial dilution for existing HSPT public shareholders, and the required additional financing is not yet secured. Furthermore, identified material weaknesses in internal controls and regulatory uncertainties add to the risk profile. While the long-term potential is considerable, the immediate risks and lack of commercialized products suggest a 'hold' position for investors to monitor progress on clinical trials, financing, and operational improvements before making a more definitive investment decision.

Keywords

SPAC, Biomedical, Merger, Acquisition, Cell Therapy, Gene Therapy, Cancer Treatment, Armed-T, Gamma Delta T Cells, Exosomes, Skincare, Nasdaq Listing, SEC Filing, HSPT, SL Bio, PubCo, Clinical Trials, Biotechnology, Taiwan, FDA Regulation, Dilution, Corporate Governance, Risk Factors, Financial Reporting